One year after submitting a New Drug Application for Azstarys, the U.S. Food and Drug Administration approved KemPharm’s novel ADHD drug for use in patients 6 years and older.

Supernus Pharmaceuticals Inc.’s experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study in adults.

ADHD (attention-deficit/hyperactivity disorder) may be more common in elite athletes, a new research review suggests.

Supernus Pharmaceuticals Inc.’s experimental drug SPN-812 for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents.

There may be a strong connection between asthma and attention deficit hyperactivity disorder (ADHD) that makes people with one condition more likely to develop the other one, a recent study suggests.

Almost one year after filing a New Drug Application for an ADHD drug and less than one year after announcing it secured $200 million in financing, Ironshore Pharmaceuticals closed its doors.

Shire said it would create two distinct business units for the London-listed pharmaceutical group’s rare disease and hyperactivity medicines before deciding later this year whether to spin off the latter into a separately listed group.

Shares of Neos Therapeutics soared more than 38 percent after PDL BioPharma announced its intention to acquire the company in an all-cash deal that could total about $287 million.

Shire Plc and Shionogi & Co. Ltd. said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world’s third-biggest market for ADHD treatments.

Although the dust may have settled from a Canadian lawsuit Eli Lilly lost over patents for two of its drugs, Zyprexa and Strattera, questions remain over the manner in which the Indianapolis-based company fought in court.